Kan Yonemori

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Kan Yonemori

Jan 29, 2025, 17:41 | Insight

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo has been approved by The FDA…

Jan 4, 2025, 15:18 | Insight

Vivek Subbiah: Top Phase 1 clinical trial publications of 2024

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…

Oct 18, 2024, 15:29 | Insight

Vivek Subbiah: The power of Tissue-Agnostic in Precision Medicine

Vivek Subbiah shared a post by Antonio Calles, Head, Lung Cancer Unit at Hospital Ruber Internacional, on…

Sep 19, 2024, 09:29 | Insight

Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine

Guilherme Nader Marta, Advanced Clinical Fellow - Dana-Farber Cancer Institute, shared a post on LinkedIn: "DESTINY-Breast06…

Jun 5, 2024, 15:22 | Insight

Piotr Wysocki: T-DXd in metastatic ER+/HER2-low breast cancer patients after endocrine treatment failure

Piotr Wysocki recently posted on LinkedIn: "Results of a Destiny-Breast06 trial have been presented by…

All: 5 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023